Veru shares surge 16.59% premarket after positive Phase 2b trial results and FDA regulatory clarity for enobosarm in obesity treatment.

Veru Inc. (NASDAQ: VERU) surged 16.59% in premarket trading following the release of positive Phase 2b QUALITY trial results for enobosarm, demonstrating 100% lean mass preservation and 12% greater fat loss compared to placebo when combined with GLP-1 RA. The FDA provided regulatory clarity, confirming enobosarm 3 mg as an acceptable dose and endorsing incremental weight loss as a primary endpoint for potential approval. Additionally, the company secured $23.4 million in net proceeds from a public offering, strengthening its balance sheet ahead of the planned Phase 2b PLATEAU study in Q1 2026. These developments, highlighting enobosarm’s potential as a next-generation obesity treatment addressing weight loss plateaus and muscle preservation, drove investor optimism despite broader mixed Q4 2025 earnings results.